Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- University of Washington
- Study ID
- NCT02537769
- Status
- Recruiting
Conditions
- Heart Failure NYHA Class III
- Heart Failure NYHA Class IV
- Tricuspid Regurgitation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Left ventricular assist device (LVAD) — DEVICELeft ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
- Tricuspid Valve Repair (TVR) — PROCEDUREParticipants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
Study Details
The use of implantable left ventricular assist devices (LVAD) has increased over the last decade; partly because the newer continuous flow pumps feature a smaller design and better durability. These pumps have shown improved outcomes for those patients who don't qualify for heart transplantation and receive the LVAD device as a permanent therapy or a bridge to heart transplantation. Despite these improved outcomes, procedure related length of hospitalization for LVAD implantation is still 2 or 3 times that of other heart surgery treatments. One important reason for this is that many people experience right ventricular dysfunction after LVAD implantation. Treatment options for this are limited. Many LVAD patients with right ventricular dysfunction also have tricuspid valve regurgitation (TR). This is the failure of the tricuspid valve (TV) to close completely so that blood leaks backwards. Some recent studies suggest that correction of the TV during LVAD implantation has improved survival for those with severe regurgitation. However, this has not been evaluated for mild or moderate regurgitation. The goal of this study is to look at the clinical impact of surgical correction of mild to moderate TR in participants who are also undergoing LVAD implantation. The study will look at the degree of TR at various time points post-surgery, as well as any major cardiac adverse events, duration of hospitalization, and quality of life. The investigators hope to show that surgical correction of mild to moderate TR in LVAD patients will reduce right ventricular dysfunction and have a positive impact on health outcomes.
Key Dates
- Start date
- Aug 31, 2015
- Status verified
- Feb 2021
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: LVAD+TVRIn addition to left ventricular assist device (LVAD) placement with the inflow cannula in the left ventricular apex and outflow cannula placed in the ascending aorta, a repair of the regurgitating tricuspid valve will be performed. A Patent Foramen Ovale, if present, will be closed primarily. Echocardiographic parameters relevant to study will be collected throughout the procedure.
- Active Comparator: LVAD onlyLVAD placement will be performed without additional tricuspid valve repair (TVR). The inflow cannula will be sutured to the left ventricular apex followed by the outflow cannula placed in the ascending aorta. This will be performed under cardiopulmonary bypass. Echocardiographic parameters relevant to study will be collected throughout the procedure.
Primary Outcome Measure
Change in TR severity assessment from baseline [ Time Frame: 13 months ]
Central Contacts
- Cynthia Wu206-616-1893
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Washington Medical Center | Seattle | Washington | 98195 |
Find similar trials in Seattle, WA
Related Studies
- Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical TrialRecruiting · Edwards Lifesciences · Phoenix, Arizona
- EFS of the DUO System for Tricuspid RegurgitationRecruiting · CroiValve Limited · Phoenix, Arizona
- PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and IIIRecruiting · Endotronix, Inc. · Phoenix, Arizona
- TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)Recruiting · P+F Products + Features USA Inc. · Phoenix, Arizona